Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ: SUPN · Real-Time Price · USD

32.15

+0.45 (1.42%)

At close: May 12, 2025, 4:00 PM

32.50

+0.35 (1.09%)

After-hours: May 12, 2025, 7:16 PM EDT

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Supernus Pharmaceuticals stock have an average target of 36, which predicts an increase of 11.98% from the current stock price of 32.15.

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$36	$36	$36	$36
Change	+11.98%	+11.98%	+11.98%	+11.98%

* Price targets were last updated on Feb 26, 2025.

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25	May '25
Strong Buy	0	0	0	0	0	0
Buy	0	0	0	0	0	0
Hold	1	1	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $36	Hold	Reiterates	$36	+11.98%	Feb 26, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy → Hold Downgrades $57 → $36	Buy → Hold	Downgrades	$57 → $36	+11.98%	Feb 19, 2025
David Amsellem Piper Sandler	Piper Sandler	Buy → Hold Downgrades $41 → $36	Buy → Hold	Downgrades	$41 → $36	+11.98%	Sep 11, 2024
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $45 → $41	Buy	Maintains	$45 → $41	+27.53%	Feb 28, 2024
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $42 → $43	Buy	Maintains	$42 → $43	+33.75%	Nov 9, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

637.19M

from 661.82M

-3.72%

from 661.82M

Revenue Next Year

695.45M

from 637.19M

9.14%

from 637.19M

EPS This Year

2.00

from 1.32

51.71%

from 1.32

EPS Next Year

2.59

from 2.00

29.37%

from 2.00

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	520.40M	579.78M	667.24M	607.52M	661.82M	637.19M	695.45M	773.55M
Revenue Growth	32.50%	11.41%	15.09%	-8.95%	8.94%	-3.72%	9.14%	11.23%
EPS	2.36	0.98	1.04	0.02	1.32	2.00	2.59	3.27
EPS Growth	12.38%	-58.48%	6.32%	-98.08%	6,500.00%	51.71%	29.37%	26.18%
Forward PE	-	-	-	-	-	16.05	12.41	9.83
No. Analysts	-	-	-	-	-	7	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	661.1M	738.3M	824.3M
Avg	637.2M	695.5M	773.6M
Low	605.9M	645.8M	712.4M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-0.1%	15.9%	18.5%
Avg	-3.7%	9.1%	11.2%
Low	-8.4%	1.4%	2.4%

EPS Forecast

EPS	2025	2026	2027
High	2.24	2.81	3.47
Avg	2.00	2.59	3.27
Low	1.77	2.35	3.05

EPS Growth

EPS Growth	2025	2026	2027
High	69.4%	40.5%	33.7%
Avg	51.7%	29.4%	26.2%
Low	34.4%	17.4%	17.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.